Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease

Blood

Volumn 114, Issue 21, 2009, Pages 4639-4644

  Gordeuk, Victor R ^a   Campbell, Andrew ^b   Rana, Sohail ^a   Nouraie, Mehdi ^a   Niu, Xiaomei ^a   Minniti, Caterina P ^c   Sable, Craig ^d   Darbari, Deepika ^d   Dham, Niti ^d   Onyekwere, Onyinye ^a   Ammosova, Tatiana ^a   Nekhai, Sergei ^a   Kato, Gregory J ^c   Gladwin, Mark T ^e   Castro, Oswaldo L ^a  

^a HOWARD UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN F; HYDROXYUREA; ANTISICKLING AGENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD LEVEL; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; HYPOXIA; LABORATORY TEST; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SICKLE CELL ANEMIA; STEADY STATE; TRICUSPID VALVE REGURGITATION; BLOOD; DRUG EFFECT; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; ERYTHROPOIETIN; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; MALE; TRICUSPID VALVE INSUFFICIENCY; YOUNG ADULT;

EID: 73949092418     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-218040     Document Type: Article

References (40)

1. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
2. Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica. 2007;92(11):1549-1552.
3. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009;94(3):340-347.
4. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
5. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
6. Taylor JGt Ackah D, Cobb C, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol. 2008;83(1):6-14.
7. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 1990;323(6):366-372.
8. Ballas SK, Marcolina MJ, Dover GJ, Barton FB. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol. 1999;105(2):491-496.
9. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006;108(1):184-191.
10. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310-318.
11. Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004;117(9):665-669.
12. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109-115.
13. Akgül F, Yalcin F, Seyfeli E, et al. Pulmonary hypertension in sickle-cell disease: comorbidities and echocardiographic findings. Acta Haematol. 2007;118(1):53-60.
14. Aleem A, Jehangir A, Owais M, et al. Echocardiographic abnormalities in adolescent and adult Saudi patients with sickle cell disease. Saudi Med J. 2007;28(7):1072-1075.
15. Vicari P, de Cassia Rosario Cavalheiro R, de Gouveia A, Filho Campos O, Figueiredo MS. Echocardiographic abnormalities in Brazilian sickle cell patients. Am J Hematol. 2005;78(2):160-161.
16. Nelson SC, Adade BB, McDonough EA, Moquist KL, Hennessy JM. High prevalence of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29(5):334-337.
17. Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica. 2007;92(6):738-743.
18. Aliyu ZY, Gordeuk V, Sachdev V, et al. Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol. 2008;83(6):485-490.
19. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447-5454.
20. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood. 1999;94(6):1864-1877.
21. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation. 2006;113(11):1442-1450.
22. Allegra A, Giacobbe MS, Corvaia E, et al. Possible role of erythropoietin in the pathogenesis of chronic cor pulmonale. Nephrol Dial Transplant. 2005;20(12):2866-2867.
23. Buemi M, Senatore M, Gallo GC, et al. Pulmonary hypertension and erythropoietin. Kidney Blood Press Res. 2007;30(4):248-252.
24. Klings ES, Anton Bland D, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol. 2008;83(7):547-553.
25. Papassotiriou I, Kister J, Griffon N, et al. Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998;102(5):1165-1171.
26. Perutz M. Molecular anatomy and physiology of hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin. Cambridge, United Kingdom: Cambridge University Press; 2001:194-196.
27. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A. 1979;76(2):670-672.
28. Sunshine HR, Hofrichter J, Ferrone FA, Eaton WA. Oxygen binding by sickle cell hemoglobin polymers. J Mol Biol. 1982;158(2):251-273.
29. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
30. Miller DM, Winslow RM, Klein HG, Wilson KC, Brown FL, Statham NJ. Improved exercise performance after exchange transfusion in subjects with sickle cell anemia. Blood. 1980;56(6):1127-1131.
31. Camaschella C, Gonella S, Calabrese R, et al. Serum erythropoietin and circulating transferrin receptor in thalassemia intermedia patients with heterogeneous genotypes. Haematologica. 1996;81(5):397-403.
32. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921-926.
33. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
34. Voskaridou E, Bilalis E, Christoulas D, et al. Prolonged administration of hydroxyurea reduces morbidity and mortaiity in adult patients with sickle-cell syndromes: long-term experience of a single center [abstract]. Blood. 2008;112(11):515.
35. Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25(8):629-634.
36. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79(10):2555-2565.
37. Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients. Hematol J. 2000;1(5):295-300.
38. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol. 2009;144(5):736-741.
39. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008;55(2):483-501.
40. Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol. 2008;140(1):104-112.